Cardiac Clinical Trial Studies Use of Antibiotic In Preventing Heart Attack

HIGHLIGHTS: A clinical trial currently under way at Cedars-Sinai Medical Center could have profound ramifications for preventing recurring heart attacks by using a common, inexpensive antibiotic. AVAILABLE FOR INTERVIEWS: Bojan Cercek, M.D., Ph.D., Director, Coronary Care Unit, Cedars-Sinai Medical Center P.K.Shah, M.D., Chairman, Division of Cardiology, Cedars-Sinai Medical Center; Professor of Medicine, UCLA School of Medicine. LOS ANGELES (November 12, 1998) - A common, inexpensive antibiotic could reduce a second heart attack in patients who have already suffered an acute heart attack. In a clinical trial involving 1,400 patients, Cedars-Sinai Medical Center scientists, as well as collaborators at two facilities in Israel and three in Europe, are testing the effectiveness of the common antibiotic, Azithromycin, in preventing recurrent heart attacks.

"Of people who have just had a heart attack, 20 to 25 percent are likely to have another heart attack within the next six months," says Bojan Cercek, M.D., Ph.D., Lead Investigator and Director of the Coronary Care Unit at Cedars-Sinai.

"There is a growing body of scientific evidence implicating ongoing inflammation (accumulation of white blood cells) in plaque formation and plaque disruption that leads to blood clots and heart attacks, says P.K.Shah, M.D., Chairman of Cardiology at Cedars-Sinai.

According to Dr. Shah, "Cholesterol accumulation inside the plaque provides one of the stimuli for inflammation; the other may be bacterial/viral infection of the plaque. Therefore we designed the current AZACS study to determine the potential value of antibiotics for heart attack prevention."

"Chlamydia pneumonia, a common bacteria that causes respiratory infections, has been identified in 30 to 40 percent of plaques where it may stimulate the white blood cells to trigger a heart attack," says Dr. Cercek. "If this hypothesis is correct, treating the patient with the antibiotic Azithromycin

Contact: Sandra Van
Cedars-Sinai Medical Center

Page: 1 2

Related biology news :

1. Cardiac arrest may hinder ability to learn certain tasks
2. Cardiac stress tests may indicate if blockages will recur after angioplasty with stent implant
3. Cardiac surgery patients at higher risk
4. Sudden Cardiac Death May Run In Families
5. New Company Formed Through Licensing Of Cardiac-Hypertrophy Technology From Texas Institutions
6. Strategic Placement Of Automated External Defibrillators May Help Save Lives Of People Who Go Into Cardiac Arrest
7. Evaluation Of The Two Types Of Cardiac Pacemakers Indicates Only Modest Differences In Value
8. Family Ties To Sudden Cardiac Arrest; Study Finds Risk Goes Up 50 Percent
9. Study Reviews Medication Use In Elderly Cardiac Patients After Discharge
10. Researchers Find Association Between Alzheimers Gene And Mental Impairment After Cardiac Surgery
11. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK

Post Your Comments:

(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable ... support testing operations in the fight against the COVID-19 pandemic in Zambia. , ...
Breaking Biology News(10 mins):
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... The ... and security leaders as the 2020 winners of the Women in Biometrics Awards ... sponsors IDEMIA , Biometric Update and the SIA Women in ...
(Date:5/21/2020)... ... , ... Threats to intellectual property, political pressure to lower ... wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new ... commercially weaker, dealing with delays in new product launches and with fewer resources ...
(Date:5/21/2020)... ... ... Eaton Square is pleased to announce its growth on the East Coast of ... strategy and M&A advisory firm. , This is an important step for Eaton Square ... healthcare innovators with capital and investors. , Popper and Company, founded in 2003 by ...
(Date:5/15/2020)... (PRWEB) , ... May 14, ... ... supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC ... to enable streamlined and multi-format collection of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC ...
Breaking Biology Technology:
Cached News: